ArticleFrontiers in cardiovascular medicine2025
Global, regional, and national burdens of lower extremity peripheral arterial disease from 1990 to 2021 and projections to 2050: global burden of disease study 2021.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The global and regional burden of lower extremity peripheral artery disease (LEPAD) and its trends have not been systematically studied. Utilizing data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, this study analyses the global burden and associated risk factors for LEPAD from 1990 to 2021 and predicts its incidence trends to 2050. Methods: LEPAD-related data including the number of morbidity, mortality, disability-adjusted life years (DALYs), age-standardized rate (ASR), were extracted from the GBD 2021 database. The analysis assesses the burden stratified by social demographic index (SDI), age, and sex. Bayesian age-period-cohort (BAPC) models were used to predict the future age-standardized incidence. Findings: The global incidence, death, and DALY of LEPAD increased significantly between 1990 and 2021; however, age-standardized incidence rate (ASIR), age-standardized rates of death (ASMR), and age-standardized disability-adjusted life years (ASDR) have shown an overall decline. In addition, ASIR and SDI were positively correlated. Age-specific analyses revealed that ASMR increased with age. The predictions from the BAPC model indicate a slight increase in ASIR over the next 29 years. While high fasting glucose dominated LEPAD DALYs, summary exposure value (SEV) metrics exposed high Low-Density Lipoprotein Cholesterol (LDL-C) as the primary metabolic exposure burden, highlighting a critical prevention gap. Interpretation: The burden of LEPAD increases progressively with age, and its prevalence is influenced mainly by the SDI. Despite the increased incidence of LEPAD in women, mortality and DALYs were substantially higher in men. The global burden of LEPAD is projected to increase progressively by 2050, representing a major health concern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.